Ardelyx News and Activities
Presence
Ardelyx develops and sells medicines for kidney and digestive diseases. It offers prescription treatments and patient support services for doctors, patients, and healthcare providers.
Ardelyx products and services overview:
- Kidney disease drugs
- Digestive disease drugs
- Prescription medicines
- Patient support services
Revenue: ~$400 million
Employees: 300
Headquarters: Waltham, United States (USA)
Ardelyx is one of the...
Ardelyx is a company listed under the stock ticker ARDX (US).
Executives
View the org chart displaying its 38 main executives
Most searched biographies at Ardelyx
- Mike Raab, President and Chief Executive Officer
- Onaiza Cadoret-Manier, Director
- William Bertrand, Director
Popular executive movements at Ardelyx
- Elizabeth Grammer, Chief Legal and Administrative Officer, is retiring (posted on April 21 2026).
- Felecia Ettenberg has joined the company as Chief Legal Officer (posted on April 21 2026).
- Rajani Dinavahi has joined the company as Chief Medical Officer (posted on April 1 2026).
Click here to view some more movements at Ardelyx
Create your alert
to follow the executive moves at Ardelyx.
Biotechnology
Ardelyx has 2,424 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).
Popular M&A news in Biotechnology
- The new name of EG 427 is Cyllene Therapeutics. (posted on July 10 2026).
- Opthea will change its company name to Ceryvyn Therapeutics on Jul 9, 2026. (posted on July 9 2026).
- Tissium has just announced a $60 Million fundraising (posted on July 8 2026).
Popular contacts in Biotechnology
News
Press releases by Ardelyx
- Ardelyx to Present at the 2022 Wedbush PacGrow Healthcare Conference | Ardelyx, Inc.
- Ardelyx to Report Second Quarter 2022 Financial Results on August 4, 2022 | Ardelyx, Inc.
- Ardelyx, Inc. Reports Employment Inducement Grants | Ardelyx, Inc.
- Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners | Ardelyx, Inc.
- Ardelyx Announces FDA Advisory Committee Meeting to Review XPHOZAH® NDA Tentatively Scheduled for November 16, 2022 | Ardelyx, Inc.
- Ardelyx to Present at the Jefferies 2022 Healthcare Conference | Ardelyx, Inc.
- Ardelyx Presents Data at DDW 2022 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults | Ardelyx, Inc.
- Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022 | Ardelyx, Inc.
- PRESS RELEASES | Ardelyx, Inc.
- Ardelyx, Inc. Reports Employment Inducement Grants | Ardelyx, Inc.
- View more press releases Close
Social media about Ardelyx
- Ardelyx on Wikipedia, Google News & Yahoo Finance
- Ardelyx on LinkedIn, X (Twitter) & YouTube
